Sermorelin, Ipamorelin 10mg (Blend)

Sermorelin, Ipamorelin 10mg (Blend) — Dual-Action Growth Hormone Secretagogue Research Formulation

This advanced 10mg synergistic formulation pairs Sermorelin with Ipamorelin to create a highly refined, dual-mechanism architecture for neuroendocrine research. By combining a classic Growth Hormone-Releasing Hormone (GHRH) analogue with a highly selective Growth Hormone Secretagogue Receptor (GHSR) agonist, this blend allows investigators to explore amplified, pulsatile release pathways of endogenous growth hormone.

• Dual-Mechanism Pathway Synergy: Simultaneously targets distinct pituitary receptor configurations. Sermorelin stimulates the GHRH receptors, while Ipamorelin acts selectively on the ghrelin/secretagogue receptors, working in tandem to optimize cellular signaling cascades.

• Highly Selective Architecture: Engineered to evaluate growth hormone amplification without severely disrupting normal homeostatic baselines or triggering unwanted spikes in secondary hormones such as cortisol, prolactin, or aldosterone.

• Key Research Areas: Extensively utilized in metabolic, physiological, and cellular aging studies to investigate lean tissue preservation, visceral adipose tissue metabolism, and accelerated cellular repair mechanisms.

• Purity Guaranteed: $\ge 99\%$ purity of each constituent peptide within the blend, verified by rigorous HPLC and Mass Spectrometry testing to maintain exact and repeatable experimental baselines.

• Optimal Stability: Supplied as a sterile, lyophilized powder format to protect delicate peptide chains, ensuring excellent structural integrity and straightforward reconstitution for in vitro and laboratory assays.

Note: This product is sold strictly as a high-purity research chemical. It is intended solely for laboratory, in vitro, or animal research applications and is not approved for human injection, therapeutic, or diagnostic use.